<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122640">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01836172</url>
  </required_header>
  <id_info>
    <org_study_id>HW2012-YJP002</org_study_id>
    <nct_id>NCT01836172</nct_id>
  </id_info>
  <brief_title>YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus</brief_title>
  <official_title>Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Han Wha Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Han Wha Pharma Co., Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of YJP-14 capsules for the
      treatment of endothelial dysfunction in patients with diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to demonstrate superior effect of YJP-14 three doses,
      25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus indicated as pooled
      mean change difference of flow-mediated dilation (FMD), compared to placebo group after
      treatment of 12 weeks.

      The secondary purposes of this study are divided into three as following ;

      The first secondary purpose of this study is to evaluate clinically significant effect of
      YJP-14 three doses, 25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus
      indicated as pooled mean change difference of FMD, compared to placebo group after treatment
      of 4-weeks and 8-weeks.

      The second secondary purpose of this study is to evaluate clinically significant effect of
      YJP-14 three doses, 25, 50 and 100 mg t.i.d on insulin resistance in diabetes mellitus
      indicated as pooled mean change difference of Homeostasis Model Assessment-Insulin
      Resistance (HOMA-IR), compared to placebo group after treatment of 4-weeks, 8-weeks and
      12-weeks.

      The third secondary purpose of this study is to evaluate clinically significant effect of
      YJP-14 three doses, 25, 50 and 100 mg t.i.d on pooled mean change difference of blood
      pressure in diabetes mellitus, compared to placebo group after treatment of 4-weeks, 8-weeks
      and 12-weeks.

      The exploratory purposes of this study are divided into two as following ;

      The first exploratory purpose of this study is to evaluate clinically significant effect of
      YJP-14 three doses, 25, 50 and 100 mg t.i.d on blood glucose level in diabetes mellitus
      indicated as pooled mean change difference of HbA1c, compared to placebo group after
      treatment of 12-weeks.

      The second exploratory purpose of this study is to evaluate clinically significant effect of
      YJP-14 three doses, 25, 50 and 100 mg t.i.d on vascular stiffness in diabetes mellitus
      indicated as pooled mean change difference of blood lipids, LDL, HDL and TG, compared to
      placebo group after treatment of 12-weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Flow-mediated dilation (FMD)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pooled mean change difference of Flow-mediated dilation (FMD) for 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated dilation (FMD) Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) Systolic and Diastolic Blood Pressure</measure>
    <time_frame>4, 8 and 12-weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pooled mean change difference of Flow-mediated dilation (FMD) for 4 and 8 weeks Pooled mean change difference of Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) for 4, 8 and 12 weeks Pooled mean change difference of Systolic and Diastolic Blood Pressure for 4, 8 and 12 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HbA1c  Serum lipids (LDL, HDL and TG)</measure>
    <time_frame>12-weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pooled mean change difference of HbA1c for 12 weeks Pooled mean change difference of serum lipids (LDL, HDL and TG) for 12 weeks</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Diabetic Complication</condition>
  <arm_group>
    <arm_group_label>Placebo t.i.d.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YJP-14 25 mg t.i.d.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YJP-14 50 mg t.i.d.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YJP-14 100 mg t.i.d.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YJP-14</intervention_name>
    <description>An 50% ethanolic extract of Lindera obtusiloba stems</description>
    <arm_group_label>Placebo t.i.d.</arm_group_label>
    <arm_group_label>YJP-14 25 mg t.i.d.</arm_group_label>
    <arm_group_label>YJP-14 50 mg t.i.d.</arm_group_label>
    <arm_group_label>YJP-14 100 mg t.i.d.</arm_group_label>
    <other_name>An 50% ethanolic extract of Lindera obtusiloba stems</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult onset DM defined as fasting glucose greater than 125 mg/dl or by ongoing treatment
        with an oral hypoglycemic agent Endothelial dysfunction: FMD 5% below LDL cholesterol
        level less than 140 mg/dl Patients agreed to Informed Consent Form

        Exclusion Criteria: (Key exclusion criteria) Uncontrolled arterial hypertension (above
        130/90 mmHg)or hypotension (below 80/50 mmHg) Severe diabetic complication : diabetic
        nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic vascular complications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-Hee Oh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-Ok LEE, Ph.D.</last_name>
    <phone>+82-10-2867-6905</phone>
    <email>leejungok@hwpharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong-sik MOON, Ph.D.</last_name>
    <phone>+82-10-6482-2130</phone>
    <email>hsmoon@hwpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Internal medicine, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byung-Hee Oh, M.D., Ph.D.</last_name>
      <phone>+82-2-2072-3345</phone>
      <email>ohbhmed@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Byung-Hee Oh, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lee JO, Oak MH, Jung SH, Park DH, Auger C, Kim KR, Lee SW, Schini-Kerth VB. An ethanolic extract of Lindera obtusiloba stems causes NO-mediated endothelium-dependent relaxations in rat aortic rings and prevents angiotensin II-induced hypertension and endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jun;383(6):635-45. doi: 10.1007/s00210-011-0643-9. Epub 2011 May 2.</citation>
    <PMID>21533989</PMID>
  </reference>
  <reference>
    <citation>Lee JO, Auger C, Park DH, Kang M, Oak MH, Kim KR, Schini-Kerth VB. An Ethanolic Extract of Lindera obtusiloba Stems, YJP-14, Improves Endothelial Dysfunction, Metabolic Parameters and Physical Performance in Diabetic db/db Mice. PLoS One. 2013 Jun 3;8(6):e65227. doi: 10.1371/journal.pone.0065227. Print 2013.</citation>
    <PMID>23755196</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 9, 2013</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>The treatment of diabetic complication</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
